Aligos Therapeutics, Inc. – ‘10-Q’ for 6/30/22 – ‘ZIP’

On:  Thursday, 8/4/22, at 4:40pm ET   ·   For:  6/30/22   ·   Accession #:  950170-22-14815   ·   File #:  1-39617

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.09M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     24K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     24K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
11: R1          Document and Entity Information                     HTML     78K 
12: R2          Condensed Consolidated Balance Sheets               HTML    120K 
13: R3          Condensed Consolidated Balance Sheets               HTML     35K 
                (Parenthetical)                                                  
14: R4          Condensed Consolidated Statements of Operations     HTML     75K 
                and Comprehensive Loss                                           
15: R5          Condensed Consolidated Statements of Changes in     HTML     80K 
                Stockholders' Equity                                             
16: R6          Condensed Consolidated Statements of Cash Flows     HTML    112K 
17: R7          Organization                                        HTML     34K 
18: R8          Summary of significant accounting policies          HTML     30K 
19: R9          Property and equipment                              HTML     63K 
20: R10         Investments                                         HTML    129K 
21: R11         Accrued liabilities                                 HTML     45K 
22: R12         Stock-based compensation                            HTML    165K 
23: R13         Fair value                                          HTML     88K 
24: R14         License and collaboration agreements                HTML     55K 
25: R15         Commitments and contingencies                       HTML     22K 
26: R16         Income taxes                                        HTML     22K 
27: R17         Net loss per share                                  HTML     98K 
28: R18         Discontinued development of drug candidates         HTML     27K 
29: R19         Subsequent events                                   HTML     20K 
30: R20         Summary of significant accounting policies          HTML     33K 
                (Policies)                                                       
31: R21         Property and equipment (Tables)                     HTML     57K 
32: R22         Investments (Tables)                                HTML    125K 
33: R23         Accrued liabilities (Tables)                        HTML     44K 
34: R24         Stock-based compensation (Tables)                   HTML    142K 
35: R25         Fair value (Tables)                                 HTML     83K 
36: R26         Net loss per share (Tables)                         HTML     97K 
37: R27         Organization - Additional Information (Detail)      HTML     32K 
38: R28         Property and equipment - Summary of Property and    HTML     39K 
                Equipment (Detail)                                               
39: R29         Property and equipment - Additional Information     HTML     19K 
                (Detail)                                                         
40: R30         Investments - Summary of Available For Sale         HTML     31K 
                Securities Amortized Cost Gross Unrealized Gains                 
                Losses and Fair Value (Detail)                                   
41: R31         Investments - Summary of Debt Securities Available  HTML     28K 
                for Sale Maturity (Detail)                                       
42: R32         Investments - Additional Information (Detail)       HTML     21K 
43: R33         Accrued liabilities - Summary of Accrued            HTML     28K 
                Liabilities (Detail)                                             
44: R34         Stock-based Compensation - Additional Information   HTML     49K 
                (Detail)                                                         
45: R35         Stock-based Compensation - Summary of Stock         HTML     83K 
                Options (Detail)                                                 
46: R36         Stock-based Compensation - Summary of Stock Based   HTML     25K 
                Compensation Expense Was Allocated (Detail)                      
47: R37         Fair value - Summary of Fair Value of the           HTML     38K 
                Financial Instruments that are Measured at Fair                  
                Value on a Recurring Basis (Detail)                              
48: R38         License and collaboration agreements - Additional   HTML     90K 
                Information (Detail)                                             
49: R39         Commitments and contingencies - Additional          HTML     19K 
                Information (Detail)                                             
50: R40         Net loss per share - Schedule of Earnings Per       HTML     34K 
                Share Basic and Diluted (Detail)                                 
51: R41         Net loss per share - Schedule of Antidilutive       HTML     26K 
                Securities Excluded From Computation of Earnings                 
                Per Share (Detail)                                               
52: R42         Discontinued development of drug candidates -       HTML     23K 
                Additional Information (Detail)                                  
55: XML         IDEA XML File -- Filing Summary                      XML     97K 
53: XML         XBRL Instance -- algs-20220630_htm                   XML   1.59M 
54: EXCEL       IDEA Workbook of Financial Reports                  XLSX     64K 
10: EX-101.CAL  XBRL Calculations -- algs-20220630_cal               XML    120K 
 8: EX-101.DEF  XBRL Definitions -- algs-20220630_def                XML    438K 
 9: EX-101.LAB  XBRL Labels -- algs-20220630_lab                     XML   1.09M 
 7: EX-101.PRE  XBRL Presentations -- algs-20220630_pre              XML    733K 
 6: EX-101.SCH  XBRL Schema -- algs-20220630                         XSD    142K 
56: JSON        XBRL Instance as JSON Data -- MetaLinks              300±   467K 
57: ZIP         XBRL Zipped Folder -- 0000950170-22-014815-xbrl      Zip    286K 

‘ZIP’   —   XBRL Zipped Folder — 0000950170-22-014815-xbrl

This is an XBRL Zipped Folder.

	Download this zipped .zip folder
Files:	algs-20220630.htm algs-20220630.xsd algs-20220630_cal.xml algs-20220630_def.xml algs-20220630_lab.xml algs-20220630_pre.xml algs-ex31_1.htm algs-ex31_2.htm algs-ex32_1.htm algs-ex32_2.htm

2 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/20/20  Aligos Therapeutics, Inc.         8-K:5,8,9  10/20/20    3:234K                                   Donnelley … Solutions/FA
10/09/20  Aligos Therapeutics, Inc.         S-1/A                 19:8.9M                                   Donnelley … Solutions/FA